8-K - Rocket Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Rocket Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its gene therapy KRESLADI™ for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). With the approval, the FDA granted the company a Rare Pediatric Disease Priority Review Voucher, which it intends to evaluate strategic options to monetize.

Key Takeaways

1FDA granted accelerated approval for KRESLADI™ (marnetegragene autotemcel) gene therapy on March 27, 2026.

2KRESLADI™ is indicated for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available HLA-matched sibling donor.

3Approval was based on increase in neutrophil CD18 and CD11a surface expression, with confirmation of clinical benefit pending longer-term follow-up data.

4FDA granted Rocket Pharmaceuticals a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval.

5Company intends to evaluate strategic options to monetize the PRV to enhance financial flexibility and maximize shareholder value.

6Company will host an investor conference call on March 27, 2026, at 8:30 AM ET.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or oth

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated March 27, 2026. 104 Cover Page Interactive Data File

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EXHIBIT 99.1